Seven Fleet Capital Management LP trimmed its holdings in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Free Report) by 13.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 610,785 shares of the company’s stock after selling 98,730 shares during the quarter. Seven Fleet Capital Management LP owned about 0.94% of Eupraxia Pharmaceuticals worth $4,037,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors also recently bought and sold shares of the company. Vivo Capital LLC bought a new stake in Eupraxia Pharmaceuticals during the third quarter worth about $7,965,000. Affinity Asset Advisors LLC increased its stake in shares of Eupraxia Pharmaceuticals by 429.7% during the first quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock valued at $11,504,000 after purchasing an additional 1,289,005 shares in the last quarter. Jupiter Topco LLC bought a new position in shares of Eupraxia Pharmaceuticals during the second quarter valued at approximately $6,851,000. Redmile Group LLC purchased a new position in shares of Eupraxia Pharmaceuticals during the first quarter valued at approximately $5,068,000. Finally, Rubric Capital Management LP purchased a new position in shares of Eupraxia Pharmaceuticals during the first quarter valued at approximately $5,004,000.
Eupraxia Pharmaceuticals Trading Up 12.0%
Eupraxia Pharmaceuticals stock opened at $8.40 on Friday. Eupraxia Pharmaceuticals Inc. has a 1 year low of $5.15 and a 1 year high of $9.32. The firm’s 50 day moving average price is $6.68 and its 200-day moving average price is $7.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 16.00 and a quick ratio of 16.00. The stock has a market cap of $546.17 million, a P/E ratio of -8.24 and a beta of 1.07.
Analyst Ratings Changes
Several analysts recently weighed in on EPRX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Friday, July 17th. Stifel Nicolaus assumed coverage on Eupraxia Pharmaceuticals in a research report on Thursday, May 21st. They issued a “buy” rating and a $25.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eupraxia Pharmaceuticals in a report on Wednesday, July 15th. Wall Street Zen downgraded Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Finally, Oppenheimer began coverage on Eupraxia Pharmaceuticals in a research note on Thursday, June 25th. They issued an “outperform” rating and a $17.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $18.00.
View Our Latest Report on EPRX
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.
Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.
Read More
- Five stocks we like better than Eupraxia Pharmaceuticals
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
